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Aims: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine
conditions such as hyperprolactinemia is unknown.
Methods and results: We performed a cross-sectional, case–control echocardiographic study to assess the
valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control
subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18–1718 mg.
Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two
cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between
cabergoline dose and the presence or severity of mitral valve regurgitation (PZNS). Mitral valve tenting
area was significantlygreater in the cabergoline group when compared with the control subjects (PZ0.03).
Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with
the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction.
Conclusion: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects
treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to
cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes
in mitral valve geometry cannot be completely excluded.
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Over the last decade, ergoline dopamine agonists have
been increasingly used for treating patients with
Parkinson’s disease (1). These patients taking either
cabergoline or pergolide are at increased risk of newly
diagnosed degenerative heart valve disease, which is
mostly mediated by the activation of the subtype 2
5-hydroxytryptamine receptor (5-HT2B) (2). The 5-HT2B
receptor is highly expressed in human heart valves. When
stimulated, it promotes mitogenesis and proliferation of
fibroblasts, resulting in an overgrowth valvulopathy (3, 4).
In Parkinson’s disease, the severity of cardiac valve
regurgitation is directly related to the cumulative exposure
to (duration and dose) cabergoline and pergolide (5–8).
Cabergoline is also a first-line agent for treating
patients with prolactinomas, the major cause of
hyperprolactinemia (9). Nevertheless, cardiac valve
disease has not been reported as a risk in these patients
who may require long-term, or even lifelong, treatment
with dopamine agonist therapy. The absence of valvular
lesion could be related to the absence of a systematic
echocardiographic examination of cardiac valves in
these patients, a case–control study lacking to date. As
the doses of cabergoline used in hyperprolactinemia
(10, 11) (weekly dose of 0.25–3.5 mg) are considerably
lower than those used in Parkinson’s disease (daily dosendocrinologyof 2–6 mg), it would be reasonable to assume a lower
risk of valvular lesions (12). However, because dopa-
mine agonist treatment usually starts at a young age
and might be continued for up to three decades, the
potential safety of low-dose cabergoline therapy might
be counterbalanced. Whether young patients receiving
low-dose cabergoline therapy for such a long period are
at increased risk of valve disease is currently unknown.
Moreover, the risk of valvular lesions might be greater in
patients with resistant prolactinomas who require
higher doses of cabergoline.
We hypothesized that long-term treatment with
cabergoline for endocrine disease would be associated
with an increased risk of cardiac valve lesions. To test
this hypothesis, we undertook a cross-sectional, case–
control echocardiographic study to identify the presence
of cardiac valve disease and to quantify its severity in a
cohort of patients receiving cabergoline for at least
1 year for the treatment of hyperprolactinemia.Methods
Patient population
Between January and August 2007, all consecutive
patients attending our outpatient endocrine clinic whoDOI: 10.1530/EJE-08-0213
Online version via www.eje-online.org
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screened for inclusion as subjects in this study. To be
eligible, subjects had to have received treatment with
cabergoline for at least 12 months. Exclusion criteria
were: a previous history of cardiac valvular abnormal-
ities, the previous use of anorectic drugs or drugs that
caused hyperprolactinemia, and the presence of a
pituitary adenoma that hypersecreted both prolactin
and growth hormone (GH) (as GH is independently
associated with cardiac disease). Subjects that had
hyperprolactinemia secondary to medication intake
were not enrolled. Subjects with echocardiographic
evidence of major cardiac and valvular abnormalities
associated with a specific cause such as valvular
calcifications, regurgitation associated with annular
dilatation and left ventricular dysfunction or excessive
leaflet motion were not included.
The study population consisted of 102 subjects who
received cabergoline for the treatment of prolactinoma
(nZ90), idiopathic hyperprolactinemia (nZ6), and non-
secreting pituitary adenomas (nZ6). Before receiving
cabergoline, 30 subjects had received bromocriptine
for a range of 2 months to 12 years (!1 yearZ15
subjects; 1 year to !5 yearsZ8 subjects; and 5 to 12
yearsZ4 subjects). Three patients received bromocriptine
(duration: 10 years (nZ1) and 3 years (nZ2)) followed
by quinagolide (duration: 2 years (nZ1) and 3 years
(nZ2)). One subject received quinagolide alone for
3 months before cabergoline therapy. The cumulative
dose of cabergoline was calculated for each patient as the
sum of the doses used multiplied by the months of
treatment (from the beginning of intake to the day of
echocardiography).
A control group was recruited among healthy
members of the hospital staff and from subjects
attending the echocardiographic laboratory for evalu-
ation of fitness or coronary risk factors. Exclusion
criteria were the same as for the cabergoline-treated
group and in particular, none had hyperprolactinemia
or had ever received dopamine agonists or anorectic
drugs. A pool of 82 subjects was identified and screened;
from these, 51 control subjects were matched for age
and sex in a 1:2 ratio with the cabergoline group. The
two groups were also matched for the presence of major
cardiovascular risk factors such as diabetes mellitus,
hypertension, dyslipidemia, and history of coronary
artery bypass grafting. The protocol was approved by
the Institutional Review Board of the Centre Hospitalier
Universitaire, Lie`ge (Belgian Clinical Trial Number
B70720072649; Belgian Online Registry of Human
Studies www.clinicatrials.be) and all patients provided
written informed consent.Echocardiographic measurements
All patients and controls underwent a complete
transthoracic echocardiographic examination using
the same equipment (Vivid 7 GE, Vingmed Ultrasound,www.eje-online.orgHorten, Norway). All echocardiograms were performed
by two experienced echocardiographers, with special
attention towards valvular status and were interpreted
by a third echocardiographer who was blinded to the
study groups. Echocardiographic and Doppler data were
obtained in digital format and stored on optical disks for
off-line analysis. Valvular regurgitation was diagnosed
using color-coded Doppler and by imaging multiple
views. Quantification of regurgitant valve disease was
made according to the guidelines of the American
Society of Echocardiography (13). Valve regurgitation
was graded as mild, moderate, or severe. Abnormal
leaflet or cusp thickening was judged to be present when
the thickness, local or widespread, exceeded 5 mm (6, 8).
Mitral and tricuspid valves were regarded as restrictive if
leaflet stiffening and retraction towards the apex was
identified. Mitral valvular tenting area – a marker of the
apical displacement of mitral leaflets – was obtained from
the parasternal long axis view at mid-systole and
measured the area enclosed between the annular plane
and the mitral leaflets (14, 15). The aortic valve was
judged as being restrictive if the valve opened with
evident doming of leaflets. Systolic pulmonary artery
pressure was estimated from the systolic trans-tricuspid
pressure gradient (in mmHg) using the simplified
Bernoulli equation (DPZ4V2, where VZmaximal
tricuspid regurgitant velocity in m/s).Statistical analysis
Variables were expressed as medians, ranges, and
meanGS.D. Differences between means were analyzed
using Student’s t-test. Categorical variables were
compared with the c2-test (STATISTICA version 6,
StatSoft, Inc., Tulsa, OK, USA). All P values were
calculated on the basis of two-sided tests, and a P!0.05
was considered significant. A linear regression analysis
was used to assess the relationship between cumulative
dose and mitral tenting area.Results
Study population
The characteristics of patients and controls are listed in
Table 1, which shows the matching of the group according
to age, sex, and the prevalence of coronary risk factors.
None of the cabergoline-treated patients had symptoms
related to cardiac valve disease. The cabergoline dose
ranged from 0.25 to 5.25 mg per week. The cumulative
dose ranged from 18 to 1718 mg (median 204 mg) over a
period of 12–228 months (median 79 months).Valvular regurgitation
The prevalence of valvular regurgitation is reported in
Table 2. Both in patients and control subjects,








Age – year* 48G12 51G14 NS
Female sex – no. (%) 32 (63) 73 (72) NS
Smoker – no. (%) 5 (10) 14 (14) NS
Diabetes mellitus – no. (%) 8 (16) 11 (11) NS
Hypertension – no. (%) 10 (20) 23 (23) NS
Dyslipidemia – no. (%) 18 (35) 35 (34) NS
History of CABG – no. (%) 1 (2) 1 (1) NS
Maximal daily cabergoline
dose – mg*
NA 1 (0.25–4.5) NA
Duration of cabergoline
therapy – months*
NA 79 (12–228) NA
R60 months of therapy –
no. (%)
NA 61 (60) NA
Cumulative cabergoline
dose – mg*
NA 204 (18–1718) NA
CABG, coronary artery bypass grafting; *Median (range); NS, not statistically
significant; NA, not applicable.
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pulmonary valve was equally prevalent and almost
exclusively mild in nature. Two cabergoline-treated
patients had moderate mitral regurgitation. The mean
cumulative dose of cabergoline in these subjects (184G
105 mg) did not differ from that in cabergoline-treated
subjects with no (276G315 mg) or mild (366G
382 mg) mitral regurgitation (PZNS). No patient had
received bromocriptine or quinagolide before cabergo-
line therapy. The mean systolic pulmonary artery
pressure could be estimated in 50 patients and 12
controls and did not differ between the two groups
(20G8 vs 20G7 mmHg, PZNS). There was no
difference in systolic pulmonary artery pressure accor-
ding to the presence or severity of mitral regurgitation
(none: 19G9 mmHg; mild: 21G6 mmHg; moderate:
22G6 mmHg; PZNS).Valvular restriction
None of the control group had evidence of leaflet
restriction in any valve (Table 2). Among patients
receiving cabergoline, six had localized (nZ4) or diffuse
(nZ2) mitral valve leaflet thickening. However, the
cumulative dose of cabergoline tended to be lower inTable 2 Valvular lesions in controls and patients.
Characteristic Controls (n
Systolic arterial pressure (mmHg) 132.3G11.9
Valvular regurgitation (n (%))
Aortic – mild/moderate/severe 5 (9.8%)/0/0
Mitral – mild/moderate/severe 22 (43.1%)/0
Tricuspid – mild/moderate/severe 21 (41.2%)/0
Pulmonary – mild/moderate/severe 19 (37.3%)/0
Valvular restriction (n (%))
Leaflet thickening of aortic/mitral/tricuspid valve 0/0/0
Mitral valve tenting area – cm2 1.23G0.22these patients than in those without mitral valve
restriction (no thickening: 331G359 mg; localized:
145G75 mg; diffuse: 171G98 mg (PZNS for all)).
Five of these patients (three with localized and two with
diffuse thickening) had mild mitral regurgitation and
one had no regurgitation. The mean tenting area
changed significantly with the extent of valvular
thickening (no thickening: 1.32G0.30 cm2; localized:
1.57G0.55 cm2 (PZNS versus none); diffuse: 1.60G
0.28 cm2 (P!0.05 versus none). Overall, the systolic
tenting area was greater in patients with diffuse/
localized mitral valve thickening than in controls
(P!0.05). Diffuse mitral valve leaflet thickening was
observed in two patients who had previously received
both bromocriptine and quinagolide before cabergoline
therapy. The duration of bromocriptine treatment in
these two patients was 3 and 10 years, while the
duration of cabergoline treatment was 40 and 70
months.
The mitral tenting area was significantly higher in
patients than in controls. The mean tenting area was
not correlated with the duration of cabergoline
treatment or the cumulative dose received. The mean
mitral tenting area did, however, increase significantly
with the increasing grade of mitral valve regurgitation
from none (1.28G0.25 cm2) to mild (1.36G0.34 cm2;
PZNS versus no regurgitation) to moderate (2.19G
0.06 cm2; P!0.001 versus no or mild regurgitation) in
patients who received cabergoline. When compared
with control subjects, the mitral tenting area was
numerically higher in treated patients with no or mild
mitral regurgitation (1.23G0.22 vs 1.32G0.29 cm2;
PZNS), but was significantly higher in patients with
moderate regurgitation (PZ0.025 versus controls). No
patient had aortic or tricuspid valvular restriction.Discussion
The risk of unsuspected moderate-to-severe cardiac
valvular lesions was not increased among patients who
received typical doses of cabergoline for the treatment of
endocrine conditions for up to 18 years. No relationship
was found between the cumulative dose of cabergoline
and the occurrence of cardiac valve lesions. This is in
contrast to the findings with cabergoline at higherZ51) Patients (nZ102) P value
128.4G14.3 NS
17 (16.7%)/0/0 NS
/0 46 (45.1%)/2 (2.0%)/0 NS
/0 51 (50%)/0/0 NS
/0 36 (35.3%)/1(1.0%)/0 NS
0/6 (5.9%)/0 NS (0.08)
1.34G0.32 0.03
www.eje-online.org
4 P Lancellotti and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008) 159cumulative exposure (O3 mg/day for O6 months) in
patients with Parkinson’s disease in whom moderate-
to-severe regurgitation was found in at least one valve
in 34% of patients (8). Leaflet restriction and fibrotic
changes of the subvalvular apparatus were the most
common morphologic changes related to cabergoline
exposure in those patients and the pathology led to
valvular insufficiency. Such findings have already had
important practical implications with the withdrawal of
pergolide from the USA market (16). Cabergoline has
not suffered the same fate as it is only indicated for the
treatment of hyperprolactinemia in the USA, but there
has been significant concern regarding the relative lack
of specific safety data in this setting (17).Cardiac valve status and cabergoline
treatment
The present echocardiographic case–control study is, to
the best of our knowledge, the first to examine the
prevalence of valvular regurgitation in a consecutive
cohort of patients treated chronically with cabergoline
for pituitary adenomas (predominantly prolactinoma)
or idiopathic hyperprolactinemia. We found that
valvular regurgitation (aortic, mitral, tricuspid, and
pulmonary) was equally prevalent in cabergoline-
treated patients and in controls. In both groups,
regurgitation was almost exclusively of a mild degree
and of no clinical significance. Two cabergoline-treated
subjects had moderate mitral regurgitation and no
subject treated with cabergoline had severe regurgita-
tion of any valve. In the two cabergoline-treated subjects
with moderate mitral regurgitation, the cumulative
dose of cabergoline was similar to that in patients with
no or mild mitral regurgitation and neither had received
bromocriptine nor quinagolide before cabergoline
therapy. It is important to note, however, that these
two patients were asymptomatic. Clinical and echocar-
diographic followup at 6 monthly intervals has been
instituted in these patients, although the clinically
effective cabergoline dose (1 and 1.5 mg a week) has not
been modified. Significant changes in mitral valvular
geometry – leaflet restriction or stiffening – as assessed
by the systolic tenting area were observed in the two
patients with moderate mitral regurgitation but not in
the other patients or controls. The tenting area was not
related to previous treatment with bromocriptine or
quinagolide. The significantly increased mitral valve
tenting area in subjects receiving cabergoline, although
not correlated with total exposure or associated with
clinical valvular compromise, is an intriguing finding.
Recent work studying the effects of ergot and derivative
dopamine agonists in Parkinson’s disease has shown a
positive relationship between treatment with dopamine
agonists and a significantly increased mitral valve
tenting area (6, 8, 18). This effect of increased, albeit
subclinical, mitral valve stiffness occurred in the
presence or absence of clinical correlates of valvularwww.eje-online.orgdamage. However, the current study is the first to show
such an effect at the much lower dopamine agonist
doses used in the treatment of endocrine disorders. The
explanation for this potential effect is unknown, but it
may herald a low-level effect of dopamine agonists via
5-HT2B receptors that warrants further study in animal
models and the maintenance of some degree of caution
regarding a potential off-target effect of this class.
Mitral valve leaflet thickening was detected in 5.9%
patients and in none of the controls; however, it was not
correlated with the cumulative dose of cabergoline. The
two patients with diffuse mitral valve leaflet thickening
had been treated with both bromocriptine and quinago-
lide before cabergoline treatment. No patient had aortic
or tricuspid valvular restriction. The mean systolic
pulmonary artery pressure – an indirect marker of the
presence of significant valvular regurgitation – was not
statistically different in treated patients and in controls.Clinical implications
Hyperprolactinemia is a highly prevalent condition,
occurring in 0.4% of the general population (19, 20).
Prolactinomas, which are the most common type of
pituitary adenoma, are the most frequent cause of
persistent hyperprolactinemia that requires dopamine
agonist therapy. Although cabergoline is usually
administered at a median dose of 1 mg/week, treatment
may be required for many years. Some patients with
hyperprolactinemia may be successfully withdrawn
from cabergoline therapy (21); however, for those
with persistent disease other treatment options are
considerably less attractive. Bromocriptine is less well
tolerated and has an unfavorable dosing regimen when
compared with cabergoline. A role for non-ergot/
ergoline dopamine agonists has been less thoroughly
validated in the treatment of hyperprolactinemia,
although data on quinagolide are available (22). The
risk–benefit ratio for surgery or radiotherapy for the
treatment of all but the largest and most resistant
prolactinomas would appear to be relatively unfavor-
able. Therefore, our results on long-term cabergoline
therapy regarding the low risk of significant valvular
lesions appear reassuring.Conclusions
Unlike in Parkinson’s disease, we found no significantly
increased risk of clinically relevant valvular regurgita-
tion in association with long-term cabergoline therapy at
the lower doses used in endocrine conditions. Cabergo-
line at a mean cumulative dose of 320 mg was
associated with a higher mitral valve tenting area than
in controls, which may indicate low-level stiffening of the
valves in the absence of more profound deformation.
While this exposure to cabergoline appears to be safe
during long-term therapy for hyperprolactinemia, an
Cabergoline and cardiac valve status 5EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008) 159association between low-dose cabergoline and altera-
tions in mitral valve geometry requires monitoring and
further investigation to determine potential causality.Conflict of interest
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